Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

GBPDC: Gut-Brain in PD Consortium Master Protocol (GBPDC)

29. dubna 2026 aktualizováno: Duke University

Consortium for Gut-Brain Communication in Parkinson's Disease Master Protocol

The purpose of this research study is to identify the role that the gut-brain axis, the group of nerves that connect the brain and gut, plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research study.

During this study, specific groups of participants, also known as "cohorts", will be identified based on the severity of their PD. There will also be a cohort enrolling participants who do not have Parkinson's and a cohort enrolling participants that are at risk for developing PD. Each of these cohorts will be compared to the others to assess the differences in the gut-brain connection.

Participants in this study will:

  • meet with a medical provider
  • answer questionnaires
  • give samples of blood, stool, and saliva
  • have X-rays taken while swallowing different foods (swallowing study)
  • have X-rays taken to see how long it takes markers to move through their colon (colon transit study)
  • have a flexible sigmoidoscopy, where a doctor looks inside the lower part of the colon and takes small tissue samples (biopsies) from the mucosa (lining)
  • have samples taken of their skin
  • have an anorectal manometry and a balloon expulsion test, where a small tube and balloon are placed in the rectum to measure muscle function.

Participation in the study will last up to 24 months (2 years).

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Detailní popis

The objectives of the master protocol are to establish a common platform that: (1) assures the collection, integration, and analysis of a set of uniformly collected data across all participating centers, and (2) follows the objective of the Gut-Brain Parkinson's Disease Consortium (GBPDC) with the goal "to enhance our understanding of the temporal onset of GI symptoms in PD and changes in gut-brain communication that can be used to leverage the potential role of the GI tract in the pathogenesis and progression of PD and to improve patient diagnosis, care, and outcomes."

Primary Objective

1. To collect prospective cross-sectional and longitudinal participant biospecimens with temporally coordinated evaluations of GI and neurological symptoms and functions to better characterize the phenotype of people with PD versus those without.

Secondary Objectives

  1. To elucidate the biological processes and pathways relevant to the role of the GI tract in the pathogenesis and progression of PD.
  2. To characterize GI symptoms, pathology, and gut-brain communication in PD to detect early and longitudinal changes in gut function and activity that correspond to the development or progression of PD.

Exploratory Objectives

  1. To identify possible novel gut-based biomarkers (functional, molecular, etc.), diagnostic tools, and therapeutic targets.
  2. To investigate the impact of neuroimmune interactions and other pathways in the GI tract on gut-brain communication and PD risk.

In conjunction with clinical, social, and environmental characterization, biospecimen collection within the GBPDC master protocol will provide the opportunity to probe and characterize the pathophysiologic underpinnings of the gut-brain axis in PD, refine existing biomarker testing for PD, and identify new biomarkers that could allow early detection of PD or new targets for treatment.

Duke University will serve as the biorepository for the GBPDC. Participants and study site personnel will collect, process, and ship biospecimens according to the GBPDC Biorepository Manual of Procedures using standard kits assembled specifically for the GBPDC master protocol. Biospecimens will be shipped from the study sites to the GBPDC central biorepository at Duke University for accessioning, storage, tracking, and subsequent distribution for use in approved future research. Throughout the conduct of the master protocol, a portion of the biospecimens received by the GBPDC central biorepository will be transferred to the NIDDK biorepository for approved research use. Any biospecimen aliquots remaining at the GBPDC central biorepository at the termination of the GBPDC program will be transferred to the NIDDK biorepository.

Statistical Design This is a prospective, observational, longitudinal cohort study designed to characterize gut-brain communication in Parkinson's Disease. The study employs a longitudinal design, including cross-sectional analyses of baseline data, to evaluate gastrointestinal and neurological functions in participants with PD compared to household controls and a prodromal cohort, as well as comparisons among PD severity subgroups.

Study Design Features:

  • Multi-center observational study across 5 GNRCs
  • Three participant cohorts: people with PD, people with prodromal features of PD, and household controls. The PD cohort will be further classified as mild, moderate, or severe PD.
  • Longitudinal design with assessments at baseline, 6, 12, 18, and 24 months
  • Comprehensive biospecimen collection coordinated with clinical assessments
  • Household control design where controls are matched to people with PD when available

Typ studie

Pozorovací

Zápis (Odhadovaný)

250

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Spojené státy
    • California
      • Stanford, California, Spojené státy, 94305
        • Stanford University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kathleen L Poston, MD, MS
        • Vrchní vyšetřovatel:
          • Laren S Beckers, MD
    • Illinois
      • Chicago, Illinois, Spojené státy, 60637
        • University of Chicago
        • Vrchní vyšetřovatel:
          • Tao Xie, MD, PhD
        • Vrchní vyšetřovatel:
          • Eugene Chang, MD
        • Kontakt:
      • Chicago, Illinois, Spojené státy, 60612
        • Rush University
        • Vrchní vyšetřovatel:
          • Ali Keshavarzian, MD
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Christopher Goetz, MD
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02114
        • Massachusetts General Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Aleksander Videnovic, MD
    • Minnesota
      • Rochester, Minnesota, Spojené státy, 55905
        • Mayo Clinic
        • Vrchní vyšetřovatel:
          • Adil Bharucha, MBBS, MD
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Rodolfo Savica, MD, PhD
    • New York
      • New York, New York, Spojené státy, 10027
        • Columbia University
        • Vrchní vyšetřovatel:
          • Braden Kuo, MD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29425
        • Medical University of South Carolina
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ano

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Patients at the NIDDK designated Gastroenterology Neurology Research Centers

Popis

Inclusion Criteria (All PD Cohorts)

  1. Aged ≥21 years old and ≤80 years old
  2. Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria
  3. Adequate visual, hearing, cognitive, and physical ability
  4. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures. Because longitudinal participation is important to the scientific goals of the program, a "best estimate" of interest, commitment, and geographic feasibility for three years will be documented by the enrolling investigator after interview with the potential enrollee

Inclusion Criteria Controls

  1. Aged ≥21 years old and ≤80 years old
  2. No known or diagnosed neurodegenerative disease
  3. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures
  4. Resides within the same household as person with PD

Inclusion Criteria Prodromal Cohort

  1. Aged ≥21 years old and ≤80 years old
  2. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

Exclusion Criteria (All Cohorts)

  1. Diagnosis of secondary or atypical parkinsonism

  2. Laboratory Values:

    1. Hemoglobin (Hgb) <10
    2. Platelets <70,000
    3. Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) > 2 1/2 times upper limit of normal (ULN)
    4. Moderate or severe renal disease with an estimated glomerular filtration rate (eGFR) <60 mL/min/BSA [body surface area]) calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, or moderate or severe hepatic impairment (alkaline phosphatase [ALP] >2.0 times the ULN and/or total bilirubin >2.0 times the ULN)
    5. Significantly above the normal range for PT/INR/PTT
  3. Currently taking anticoagulants that are deemed exclusionary by the investigator for risk of bleeding with sigmoidoscopy procedure
  4. Clinically significant cognitive impairment with a Montreal Cognitive Assessment (MOCA) score <22
  5. Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than PD, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Creutzfeld-Jakob- Disease, Down's syndrome, cortico-basal degeneration, dementia with Lewy Bodies, Alzheimer's disease, amyotrophic lateral sclerosis, seizure disorder, stroke, or other infectious, metabolic, or systemic disease affecting the central nervous system including, but not limited to, syphilis, present hypothyroidism, present or unaddressed/treated vitamin B12 deficiency, or other screening laboratory abnormalities
  6. Suicidality, defined as active suicidal thoughts or ideation within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide
  7. Has cancer or has had a malignant tumor within the past 5 years. (Participants with stable untreated prostate cancer or treated/removed cutaneous carcinomas are not excluded.)
  8. Any medical condition or systemic disease that, in the Investigator's opinion, may either put the participant at risk because of participation in the study, influence the results or proposed analyses, or impair the participant's ability to fully participate in the study
  9. Body mass index (BMI) >35 kg/m2 or body weight <50 kg
  10. Participant is currently pregnant, breastfeeding, and/or lactating
  11. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria)
  12. History of Covid 19 (SARS-CoV-2) infection within 6 weeks prior to screening.
  13. Participants with unresolved symptoms of Covid 19 infection or ongoing cognitive or other deficits attributable to post-Covid 19 that may affect participant safety or interfere with cognitive assessments based on the Investigator's clinical judgment
  14. Either ongoing or current participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken. Participation in other research studies (e.g., observational studies) may be acceptable throughout this study.
  15. History of GI surgery. (However, patients with appendicectomy, hemorrhoid surgery, and cholecystectomy will be eligible to participate).
  16. Regular use of medication that impacts the intestinal barrier (e.g., NSAID more than 3 times weekly)
  17. Has a history of Crohn's disease, ulcerative colitis, and/or other types of colitis (microscopic, lymphocytic, or collagenous colitis). Confirmed diagnosis of inflammatory bowel disease (IBD) and/or, active or uncontrolled IBD symptoms such as diarrhea, bleeding, or severe stomach pain. Treatment for IBD in the past 6 months with medicines such as steroids, biologics, or strong immune-suppressing drugs. Surgery to remove part of the bowel due to IBD. Other long-term gut diseases that cause inflammation, such as celiac disease.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

Kohorty a intervence

Skupina / kohorta
Household Controls
Age-similar household controls. Household control design where controls are matched to people with PD when available.
People with Parkinson's disease
The Parkinson's Disease (PD) cohort will be further classified as mild, moderate, or severe PD as classified by Hoehn and Yahr scale.
Prodromal Parkinson's disease
People with Parkinson's Disease prodromal features. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
GI influences on PD
Časové okno: enrollment to end of observation at 24 months
Trait and State cross-sectional evaluation of GI influences on PD
enrollment to end of observation at 24 months
Co-associations components of the GBA
Časové okno: enrollment to end of observation at 24 months
Cross-sectional co-associations components of the GBA
enrollment to end of observation at 24 months

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
GBA Disruption and Parkinson's disease Progression
Časové okno: enrollment to end of observation at 24 months
GBA disruption triggered by microbiota dysbiosis (or another GI component of the GBA) predicts PD progression (both motor and non-motor dysfunction/symptoms including GI over time).
enrollment to end of observation at 24 months
GBA Disruption and Prodromal Participants
Časové okno: enrollment to end of observation at 24 months
Degree of the "type" or "nature" or "form" of the GBA disruption predict development of PD in prodromal participants over time.
enrollment to end of observation at 24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Duke University

Spolupracovníci

Medical University of South Carolina
Massachusetts General Hospital
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Chicago
Columbia University
Rush University Medical Center
Stanford University

Vyšetřovatelé

  • Vrchní vyšetřovatel: Lisa Wruck, Duke Clinical Research Institute

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Užitečné odkazy

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

4. června 2026

Primární dokončení (Odhadovaný)

31. prosince 2028

Dokončení studie (Odhadovaný)

31. prosince 2028

Termíny zápisu do studia

První předloženo

29. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

29. dubna 2026

První zveřejněno (Aktuální)

5. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. dubna 2026

Naposledy ověřeno

1. dubna 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • Pro00115811
  • 5U24DK140918-02 (Grant/smlouva NIH USA)
  • 5U01DK140933-02 (Grant/smlouva NIH USA)
  • 5U01DK140923-02 (Grant/smlouva NIH USA)
  • 5U01DK140921-02 (Grant/smlouva NIH USA)
  • 5U01DK140936-02 (Grant/smlouva NIH USA)
  • 5U01DK140939-02 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

All IPD related to the GBPDC will be shared via requests submitted through the NIDDK Central Repository.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Střevní mikrobiota

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Cote d'Ivoire

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit